---
layout: post
title: 辉瑞将以116亿美元现金收购Biohaven Pharma
date: 2022-05-10 20:33:03.000000000 +08:00
link: https://cn.wsj.com/amp/articles/%E8%BE%89%E7%91%9E%E5%B0%86%E4%BB%A5116%E4%BA%BF%E7%BE%8E%E5%85%83%E7%8E%B0%E9%87%91%E6%94%B6%E8%B4%ADbiohaven-pharma-11652182510
categories: wsj
---

<main id="main" role="main">
<div>


</div>
<div itemprop="articleLead" data-sbId="CN-FIN-20220510192528">
    <div>
      <div class="media-object scope-
          header
">
          <figure>
      <div>
        <img
          srcset="https://images.wsj.net/im-181233?width=540&amp;size=1.5005861664712778 540w, https://images.wsj.net/im-181233?width=620&amp;size=1.5005861664712778 620w, https://images.wsj.net/im-181233?width=639&amp;size=1.5005861664712778 639w, https://images.wsj.net/im-181233?width=860&amp;size=1.5005861664712778 860w, https://images.wsj.net/im-181233?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=1.5 1290w, https://images.wsj.net/im-181233?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=2 1720w, https://images.wsj.net/im-181233?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=3 2580w"
          src="https://images.wsj.net/im-181233?width=860&amp;height=573"
          layout="responsive"
          placeholder
          alt="">
        </img>
      </div>
      <figcaption>
        <p> 图片来源：Kristoffer Tripplaar/Sipa USA/Associated Press</p>
  </figcaption>
</figure>

      </div>
    </div>
</div>
<div data-sbId="CN-FIN-20220510192528">

<div>

  <div>
      <p> </p>
            <p><span itemprop="name">Ciara Linnane</span></p>

  </div>
    <time>
      2022年5月10日19:35 CST 更新
    </time>
</div>

<div>
  <social-share type="system" width="72" height="24"
    data-param-url="https://cn.wsj.com/articles/辉瑞将以116亿美元现金收购biohaven-pharma-11652182510">
  </social-share>
</div>


<div subscriptions-section="content">
</div>
<div subscriptions-section="content-not-granted">
</div>



<section subscriptions-section="content">
      <p>辉瑞公司(Pfizer Inc., PFE)周二表示，已经达成一项确定性协议，将以116亿美元现金收购Biohaven Pharmaceutical Holding Company Ltd. (BHVN)。Biohaven是双效偏头痛疗法NURTEC ODT的制造商，该疗法获批用于成人偏头痛的急性治疗和偶发预防。</p>
      <p>根据交易条款，辉瑞公司将为每股Biohaven股票支付148.50美元，股东们每拥有1股股票还将获得0.5股New Biohaven公司股票；New Biohaven将是一家新上市公司，保留Biohaven的非降钙素基因相关肽（CGRP），以及开发阶段的在研化合物。辉瑞公司还将在交易完成时（预计在2023年）支付款项，以清偿Biohaven的第三方债务并赎回优先股。</p>
      <p>148.50美元的现金对价较Biohaven在宣布交易前3个月期成交量加权平均股价111.70美元存在33%的溢价。Biohaven股价在盘前立即飙升74%；周一该股收于83.14美元。辉瑞的股价盘前下跌1.3%，今年迄今累计下跌17%，同期道指下跌11%。</p>
      <div> <p>（本文译自MarketWatch）</p>
      </div>
</section>

</div>
      </main>
